This research aims to explore how P7 peptide affects bFGF-induced malignant behaviors in ovarian cancer.
Examined the effects of P7 peptide on ovarian cancer progression.
Targeted the MEK/ERK signaling pathway for analysis.
Evaluated changes in malignant behaviors in response to P7 peptide treatment.
P7 peptide effectively inhibits bFGF-mediated progression of ovarian cancer.
Significant suppression of malignant behaviors was observed with P7 peptide treatment.
Abstract
These findings suggest that P7 peptide suppresses bFGF-mediated OC progression by targeting the MEK/ERK pathway, supporting its potential as a novel therapeutic agent in OC.